Anti-Influenza A antibody is a Mouse of Fab class that binds to an Influenza A. This antibody was the first antibody to be described with heterosubtypic reactivity, neutralizing strains from multiple subtypes, such as H1, H2, H3, and H13, that cross the HA group barrier.
Figure 1 SDS-PAGE analysis of purified S139/1 IgA and IgG antibodies.
Equal amounts (2.5 mg) of purified S139/1 IgA and IgG antibodies were analyzed by SDS-PAGE under reducing conditions (5%–20% gradient gel) (A). Polymeric forms of purified S139/1 IgA and IgG antibodies (5 mg) were analyzed under nonreducing conditions (3%–10% gradient gel) (B).
Muramatsu, M., Yoshida, R., Yokoyama, A., Miyamoto, H., Kajihara, M., Maruyama, J., ... & Takada, A. (2014). Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity. PLoS One, 9(1), e85582.
Figure 2 Comparison of binding activities of S139/1 IgA and IgG antibodies.
Binding activities of S139/1 IgA (continuous lines) and IgG (dashed lines) were tested in ELISA. Disrupted viral particles of Aichi/H3, WSN/H1, Adachi/H2, and Maryland/H13 were used as antigens. Data are mean values of duplicate wells. EC50 values calculated based on the ELISA data are shown in Table 1.
Muramatsu, M., Yoshida, R., Yokoyama, A., Miyamoto, H., Kajihara, M., Maruyama, J., ... & Takada, A. (2014). Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity. PLoS One, 9(1), e85582.
Figure 3 Comparison of neutralizing activities of S139/1 IgA and IgG antibodies.
Appropriately diluted viruses were mixed with S139/1 IgA (continuous lines) or IgG (dashed lines) at the indicated dilutions. Neutralizing activities were evaluated by counting the number of plaques formed on MDCK cells. IC50 values calculated based on the neutralization curves are shown in Table 3.
Muramatsu, M., Yoshida, R., Yokoyama, A., Miyamoto, H., Kajihara, M., Maruyama, J., ... & Takada, A. (2014). Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity. PLoS One, 9(1), e85582.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-426-F(E) | Recombinant Anti-IAV H1N1 Antibody Fab Fragment | IF, FACS, FuncS | Fab |
MHH-426-F(E) | Recombinant Human Anti-IAV H1N1 Antibody Fab Fragment | ELISA, IP, FuncS | Fab |
PFBL-110 | Recombinant Human Anti-H1N1 Antibody Fab Fragment (PFBL-110) | WB, ELISA, FuncS | Fab |
HPAB-2318LY-F(E) | Human Anti-H1N1 Recombinant Antibody; Fab Fragment (HPAB-2318LY-F(E)) | ELISA, Neut | Humanized Fab |
HPAB-2319LY-F(E) | Human Anti-H1N1 Recombinant Antibody; Fab Fragment (HPAB-2319LY-F(E)) | ELISA, Neut | Humanized Fab |
There are currently no Customer reviews or questions for PABX-118-F (E). Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.